LEO Pharma announced that the FDA has approved Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate), 0.005%/0.064% for the treatment of body plaque psoriasis for up to 8 weeks in patients ≥18 years.
In two Phase 3 clinical studies of >1,600 patients with psoriasis on the scalp, and one Phase 3 clinical study of over 1,100 patients with psoriasis on the body, a higher percentage of patients treated with Taclonex Topical Suspension achieved controlled disease than either monotherapies or vehicle used alone.
Taclonex Topical Suspension combines a vitamin D analog (calcipotriene) and a corticosteroid (betamethasone dipropionate).
Taclonex Topical Suspension is also indicated for the treatment of moderate to severe scalp psoriasis for up to 8 weeks in patients ≥18 years and is available in 30g, 60g, and 120g (2x60g) bottles.
For more information call (877) 494-4536 or visit www.leo-pharma.us.